Evidence map›Paper›PMID 32932728›Full record

ArticleInternational journal of molecular sciences2020

The New Paradigm of Network Medicine to Analyze Breast Cancer Phenotypes.

Anna Maria Grimaldi, Federica Conte, Katia Pane, Giulia Fiscon, Peppino Mirabelli, Simona Baselice, Rosa Giannatiempo, Francesco Messina, Monica Franzese, Marco Salvatore and 2 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Integrating multi-omics data: Methods and applications in human complex diseases.Biotechnology reports (Amsterdam, Netherlands) · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. In silico drug repurposing in COVID-19: A network-based analysis.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021
    Article
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Anna Maria GrimaldiIRCCS SDN, Via Emanuele Gianturco 113, 80143 Naples, Italy.ORCID 0000-0002-3957-9780
Federica ConteInstitute for Systems Analysis and Computer Science "Antonio Ruberti", National Research Council, 00185 Rome, Italy.ORCID 0000-0003-0427-1476
Katia PaneIRCCS SDN, Via Emanuele Gianturco 113, 80143 Naples, Italy.ORCID 0000-0002-7594-7931
Giulia FisconInstitute for Systems Analysis and Computer Science "Antonio Ruberti", National Research Council, 00185 Rome, Italy.ORCID 0000-0002-3354-8203
Peppino MirabelliIRCCS SDN, Via Emanuele Gianturco 113, 80143 Naples, Italy.
Simona BaseliceIRCCS SDN, Via Emanuele Gianturco 113, 80143 Naples, Italy.
Rosa GiannatiempoOspedale Evangelico Betania, Via Argine 604, 80147 Naples, Italy.
Francesco MessinaOspedale Evangelico Betania, Via Argine 604, 80147 Naples, Italy.
Monica FranzeseIRCCS SDN, Via Emanuele Gianturco 113, 80143 Naples, Italy.ORCID 0000-0002-6490-7694
Marco SalvatoreIRCCS SDN, Via Emanuele Gianturco 113, 80143 Naples, Italy.
Paola PaciDepartment of Computer, Control and Management Engineering, Sapienza University of Rome, 00185 Rome, Italy.ORCID 0000-0002-9393-2047
Mariarosaria IncoronatoIRCCS SDN, Via Emanuele Gianturco 113, 80143 Naples, Italy.ORCID 0000-0001-7019-0581

Funding

5X1000 5M-2015-2360353Ministero della Salute Ricerca Corrente RRC-2020-23669967
6 · The paper itself

Abstract

Breast cancer (BC) is a heterogeneous and complex disease as witnessed by the existence of different subtypes and clinical characteristics that poses significant challenges in disease management. The complexity of this tumor may rely on the highly interconnected nature of the various biological processes as stated by the new paradigm of Network Medicine. We explored The Cancer Genome Atlas (TCGA)-BRCA data set, by applying the network-based algorithm named SWItch Miner, and mapping the findings on the human interactome to capture the molecular interconnections associated with the disease modules. To characterize BC phenotypes, we constructed protein-protein interaction modules based on "hub genes", called switch genes, both common and specific to the four tumor subtypes. Transcriptomic profiles of patients were stratified according to both clinical (immunohistochemistry) and genetic (PAM50) classifications. 266 and 372 switch genes were identified from immunohistochemistry and PAM50 classifications, respectively. Moreover, the identified switch genes were functionally characterized to select an interconnected pathway of disease genes. By intersecting the common switch genes of the two classifications, we selected a unique signature of 28 disease genes that were BC subtype-independent and classification subtype-independent. Data were validated both in vitro (10 BC cell lines) and ex vivo (66 BC tissues) experiments. Results showed that four of these hub proteins (AURKA, CDC45, ESPL1, and RAD54L) were over-expressed in all tumor subtypes. Moreover, the inhibition of one of the identified switch genes (AURKA) similarly affected all BC subtypes. In conclusion, using a network-based approach, we identified a common BC disease module which might reflect its pathological signature, suggesting a new vision to face with the disease heterogeneity.

Indexed as

Breast NeoplasmsCell LineCell Line, TumorFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansMCF-7 CellsPhenotypeProtein Interaction MapsTranscriptomebreast cancerDisease modulesNetwork-based algorithmNetwork MedicineSwitch genes and InteractomeTCGA

Identifiers

PMID32932728
PMCPMC7555916

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.